Background/Aims: This study was conducted to investigate the assessment of treatment efficacy of radiotherapy (RT) and other therapeutic modalities compared with palliative care only for treatment with advanced hepatocellular carcinoma (HCC). Methods: From 2002 to 2010, based on the case of 47 patients with advanced HCC, we have investigated each patients' Child-Pugh's class, ECOG performance, serum level of alpha fetoprotein and other baseline characteristics that is considered to be predictive variables and values for prognosis of HCC. Out of overall patients, the 29 patients who had received RT were selected for one group and the 18 patients who had received only palliative care were classified for the other. The analysis in survival between the two groups was done to investigate the efficacy of RT. Results: Under the analysis in survival, the mean survival time of total patients group was revealed between 30.1 months and 45.9 months in RT group, while it was 4.8 months in palliative care group, respectively. In the univariate analysis for overall patients, there were significant factors which affected survival rate like as follows: ECOG performance, Child-Pugh's class, the tumor size, the type of tumor, alpha fetoprotein, transarterial chemoembolization, and RT. The regressive analysis in multivariate Cox for total patients. No treatment under radiotherapy and high level of Child-Pugh's class grade were independent predictors of worse overall survival rate in patients. In contrast, for the subset analysis of the twenty-nine patients treated with radiotherapy, the higher serum level of alpha fetoprotein was an independent predictors of worse overall survival rate in patients. Conclusions: We found that the survival of patients with advanced HCC was better with radiotherapy than with palliative care. Therefore, radiotherapy could be a good option for in patients with advanced HCC. (Korean J Hepatol 2011;17: [189][190][191][192][193][194][195][196][197][198] 
INTRODUCTION
caused by cancer only after lung cancer. 1 Because it showed relatively advanced stages at diagnosis in a variety of cases, radical hepatic resection was available only in limited cases and liver cirrhosis as a underlying disease which occurred in many cases along with multiplicity. 2, 3 As radiotherapeutic technology has currently progressed, radiotherapy has been conducted continuously in order to prevent the recurrence and to increase the survival rate after nonsurgical treatments of advanced HCC. 4 Radiotherapy is applied to HCC patients who cannot be treated with surgical resection or with a radical treatment such as a locoregional treatment and transarterial chemoembolization (TACE). It is mainly executed for patients with liver function of A or upper B
in Child-Pugh's classification, and its response rate and median survival time were reported to be 40-90% and 10-25 months, respectively. 4 The indication of radiotherapy for safe treatment, which provokes only a few side effects, is that the volume of the tumor is less than one third of the total liver volume. 5 Furthermore, the indications of extended radiotherapy show that it is less than two thirds or 70% of the total liver volume 6, 7 and that the volume irradiated with 30 Gy is less than 60% of the total liver volume in dose-volume analysis. 8 Providing a high-dose irradiation as a local irradiation, not the whole liver irradiation, has been identified, which has been continuously reported that the combination therapy of radiotherapy and chemotherapy or TACE for HCC works favorably. [9] [10] [11] What is more, in case of the patients who are not under other treatments or associating with portal vein thrombosis, [12] [13] [14] [15] radiotherapy was safe and effective to raise the survival rate. 16 The radiotherapy had the effect of relieving cancer pain, improving symptoms through the decrease of lesions, lengthening the survival time in the circumstances with the biliary obstruction of a tumor associated with jaundice, 17, 18 and extending the survival time in patients with abdominal lymph node metastasis. 19 However, even now it is not uncommon that only best palliative care can be maintained when it is hard to treat advanced HCC actively or when the general condition of a HCC patient is not appropriate. As a result, this study is focused on analyzing whether radiotherapy leads to a significant difference in the survival rate, comparing not only advanced HCC patients who have underwent treatments based on radiotherapy but also with those who have received only conservative ones.
PATIENTS AND METHODS

Patients
The critical point of this retrospective research was the were suggested as portal hypertension on endoscopy. As shown in Table 1 , the characteristics of the total subjects are summarized significantly in the pattern of classification. 
Types of HCC
In order to identify the most important variables on this research, the types of HCC were divided into massive, multinodular, and single nodular ones by following the classification of Yuki et al 21 Regardless of the existence of a satellite nodule, the massive type can be defined into a large single mass. TACE, according to priority of treatment procedures, a catheter was inserted to the hepatic artery through arteriopuncture of the ingunial area, the combination of 10 ml lipiodol and 50 mg doxorubicin as antitumor agents was injected into the hepatic artery selectively, and then gelfoam was injected lastly.
The dose for radiotherapy was not only determined by individualizing patients under their general conditions and stages, but they were also irradiated by using a 10 megavolt (MV) linear accelerator. The patients under the radiotherapy were irradiated with daily dose of 2Gy for five days per week.
Overall exposure dose was 45.9±10.6Gy in average, and 3D
conformal radiotherapy was utilized for the irradiation. The radiotherapy was performed for one patient as initial treatment and for the other 28 ones as rescue therapy.
Evaluation of response to treatment
Response to the treatment was evaluated through CT for a follow-up in 6-8 weeks after the radiotherapy. There were four significant cases associated with the size of tumor and portal vein thrombosis. The definitions for each case are followed:
Complete response (CR) was tabulated without any tumor and portal vein thrombosis. Partial response (PR) was measured into the decrease in the longest diameter of the largest nodule or the sum of the longest diameter of the largest two nodules by over 50%. No response (NR) was defined into the decrease by less than 50% or no change and the increase in the number of lumps.
Progressive disease (PD) was classified as the increase in the size of a tumor by over 25%. 25, 26 The responder group was the addition of CR and PR groups and the non-responder group was that of NR and PD groups. 25 
Statistical analysis
The frequency and proportion of patients receiving each treatment modality were calculated and tabulated with SPSS 
RESULTS
Clinical and clinicopathological characteristics
The number of all the patients registered for this study was in Child-Pugh's classification, respectively.
As shown in Comparison of characteristics between the radiotherapy and the palliative care groups, and response to radiotherapy
When the 29 patients undergoing radiotherapy were compared and analyzed with the 18 receiving only palliative care, the rate of patients who recorded two points in ECOG performance status was significantly higher (P=0.009), the rate of hepatitis C patients was also higher (P=0.025) and the grade in Child-Pugh's 
Survival analysis
The follow-up period for overall patients to be observed was (Table 3) .
After dividing the radiotherapy and the palliative care groups (Fig. 1 ).
According to multiple regression analysis through Cox regression model with the total subjects, the outcome in Table 4 shows that patients recording a lower grade in Child-Pugh's classification and undergoing radiotherapy showed significantly longer survival time even after adjusting significant factors which were observed in univariate analysis.
As shown in Table 5 , the partial analysis for 29 patients undergoing radiotherapy by univariate analysis showed that the higher an AFP level was, the shorter survival time was significantly (P=0.039). Likewise univariate analysis, multiple regression analysis which was conducted only for the radiotherapy group also revealed that the group with AFP of over 200 ng/mL had shorter survival time significantly, as shown in Table 6 .
DISCUSSION
This is a retrospective study which analyzed the survival rate by comparing the groups undergoing radiotherapy and only palliative care with HCC patients. As mentioned before, the total subjects of this study had HCC on the advanced stages, and the radiotherapy group received various treatments before and after radiotherapy.
For most patients with advanced HCC, it is difficult to treat them actively due to their poor general conditions or performance status. If radical treatment is performed for these patients excessively, the risk of death following hepatic failure can increase easily. That's the reason why non-radical treatments are applied. In the radiotherapy group, most patients underwent radiotherapy as rescue therapy (28 out of 29, 96.6%). Because of it, the response rate of this study or 37.9% was slightly lower than that observed overall in previous studies applying the irradiation of a similar dose or 40-60%. 4, 12, 27 Because radiotherapy for HCC utilized the irradiation to the whole liver in the past, there were many limitations in determining a therapeutic dose due to hepatic failure and side effects of irradiation of over a certain dose. However, it was found that high-dose irradiation to a localized part of the liver did not provoke hepatotoxicity, 17, 28, 29 and that the therapeutic dose could be raised by deciding the range for the therapy selectively.
In particular, for 3D conformal radiotherapy which was provided for most patients in this study, it is well known that it improves the survival rate of patients with advanced HCC associated with embolism by increasing its therapeutic effect, declining side effects and reaching the target radiation dose effectively compared to conventional radiotherapy. 11, 13, 25 Meanwhile, the combination of TACE and local radiotherapy has been applied continuously to primary HCC which cannot be resected, and its positive outcomes of enhancing the survival rate have been reported. 12, 30 In particular, antitumor agents, which were used during TACE to tumor cells on the tumor margin, work as radiosensitizers not only to increase the effect of radiotherapy but also to make TACE available by improving portal vein thrombosis. 4 In this study, 26 patients out of total 29 ones in the radiotherapy group (89.7%) underwent TACE before and after radiotherapy, which was considered to affect their survival rate significantly. As the mechanism was mentioned, multivariate analysis including both of TACE and radiotherapy was conducted. However, TACE did not produce any significant effect on the improvement of the survival rate in the patients who were selected on this study.
Although basic characteristics of the two groups were largely different in this study, it was only a limitation of a retrospective study reviewing the medical record, and the result was considered to be unavoidable except for a well-designed prospective study. undergoing radiotherapy, revealed that higher AFP was a prognostic factor related to the decrease of the survival rate. The finding was the same as that of previous studies reporting that increased AFP would be associated with poor prognosis. [31] [32] [33] When the results of multivariate analysis of the two groups were put together, the survival rate of advanced HCC were associated with all internal and external factors related to treatments for HCC such as the general condition of a patient (Child-Pugh's classification), the progression and the burden of a tumor (AFP) and radiotherapy. This finding strongly suggests that radiotherapy as rescue therapy for portal vein thrombosis or primary lump and regional nodal metastasis as well as efforts to improve the general condition should be provided to increase the survival rate of HCC patients.
As a retrospective study reviewing such medical records as this study has a possibility of selection bias, it should be considered in interpreting its results. This study divided the subjects into two groups receiving various treatments along with radiotherapy and doing palliative care by considering its purpose, but basic characteristics of the two groups were largely different.
In addition, this study did not consider complications due to toxicity of treatments such as radiotherapy induced liver disease (RILD) because it was hard to determine which one increased liver enzyme levels in the advanced HCC patients between radiotherapy and the disease itself. Moreover, analysis on improving the quality of life of in investigating detailed symptoms and clinical outcomes of patients after radiotherapy, is thought to be necessary.
In conclusion, if radiotherapy is available for HCC patients by synthesizing their general condition and tumor-related factors, an appropriate radiotherapy is expected to increase the survival rate. In particular, based on the results of this study when there was no distant metastasis that the type is not diffuse, AFP is less than 200 ng/mL, and the grade of Child-Pugh's classification is A or B in advanced HCC patients, radiotherapy should be considered actively as its effect so as to improve the survival rate is higher in the cases.
Prospective studies, analyzing the usefulness of radiotherapy to boost the survival rate by comparing patients with similar clinical characteristics who were treated with radiotherapy and not done, are more necessary in the future. Furthermore, as the outcomes of tomotherapy as well as of the previous 3D conformal radiotherapy have been reported continuously, prospective studies applying them and analyzing the treatment group and the non-treatment group, are expected.
